ATE456048T1 - Verfahren zur beurteilung von immunreaktionen - Google Patents

Verfahren zur beurteilung von immunreaktionen

Info

Publication number
ATE456048T1
ATE456048T1 AT05804838T AT05804838T ATE456048T1 AT E456048 T1 ATE456048 T1 AT E456048T1 AT 05804838 T AT05804838 T AT 05804838T AT 05804838 T AT05804838 T AT 05804838T AT E456048 T1 ATE456048 T1 AT E456048T1
Authority
AT
Austria
Prior art keywords
immune reactions
subset
assessing immune
immune reactivity
epitopes
Prior art date
Application number
AT05804838T
Other languages
English (en)
Inventor
Jacques Banchereau
John Connolly
Anna Palucka
Hideki Ueno
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Application granted granted Critical
Publication of ATE456048T1 publication Critical patent/ATE456048T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
AT05804838T 2004-05-24 2005-05-24 Verfahren zur beurteilung von immunreaktionen ATE456048T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57391204P 2004-05-24 2004-05-24
PCT/US2005/018418 WO2005117996A2 (en) 2004-05-24 2005-05-24 Immune response assessment method

Publications (1)

Publication Number Publication Date
ATE456048T1 true ATE456048T1 (de) 2010-02-15

Family

ID=35463368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05804838T ATE456048T1 (de) 2004-05-24 2005-05-24 Verfahren zur beurteilung von immunreaktionen

Country Status (9)

Country Link
US (1) US20060051358A1 (de)
EP (3) EP2253956A3 (de)
JP (2) JP2008507259A (de)
CN (1) CN1989410A (de)
AT (1) ATE456048T1 (de)
CA (1) CA2567491A1 (de)
DE (1) DE602005019054D1 (de)
ES (2) ES2390248T3 (de)
WO (1) WO2005117996A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228635A1 (en) * 2002-02-15 2003-12-11 Renovar, Inc. Cell proliferation assays and methods
GB0524866D0 (en) * 2005-12-05 2006-01-11 Univ Aberdeen Method of tolerisation
DE602007013620D1 (de) * 2006-09-05 2011-05-12 Hvidovre Hospital Auf IP-10 basierende immunologische Überwachung
WO2012068474A2 (en) * 2010-11-19 2012-05-24 Rutgers, The State University Of New Jersey A high-throughput asseessment method for contact hypersensitivity
CN103495157B (zh) * 2013-09-26 2016-03-16 常州牛津石松生物科技有限公司 一种dc疫苗及其制备方法和应用
US10816554B2 (en) 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
US9927443B2 (en) 2015-04-10 2018-03-27 Conquerab Inc. Risk assessment for therapeutic drugs
JP6100867B1 (ja) * 2015-11-06 2017-03-22 振武 曽 免疫状態の分析のための検査方法
ES2795440T3 (es) * 2015-12-04 2020-11-23 Agency Science Tech & Res Correlaciones clínicas de la eficacia de la inmunoterapia
US9903866B2 (en) 2016-04-05 2018-02-27 Conquerab Inc. Portable devices for detection of antibodies against therapeutic drugs
WO2020092379A1 (en) * 2018-10-29 2020-05-07 Genocea Biosciences, Inc. Treatment methods
CN111235209B (zh) * 2020-03-09 2023-08-29 山东大学齐鲁医院 一种评估干细胞免疫调控功能的方法
TW202321697A (zh) * 2021-07-16 2023-06-01 醫療財團法人徐元智先生醫藥基金會亞東紀念醫院 用於診斷輕度認知功能障礙的方法與套組
CN117607448A (zh) * 2022-06-14 2024-02-27 北京大学 免疫效度或临床相对免疫效度在评价受试者的疫苗应答强度中的应用
CN116183933A (zh) * 2023-02-21 2023-05-30 上海市第一人民医院 生物标志物组合物及其在制备评价机体免疫功能的产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2189425A1 (en) * 1994-05-03 1995-11-09 Hans Michael Dosch Methods for controlling t lymphocyte mediated immune responses
US8932806B1 (en) * 1998-01-19 2015-01-13 Florian Kern Method for identifying t-cell stimulating protein fragments
AU765085B2 (en) * 1998-05-11 2003-09-11 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific T cells
AU767391B2 (en) * 1998-10-05 2003-11-06 Genzyme Corporation Peptides related to an IGF-II-R epitope, polynucleotides encoding the peptides, and their use in immunomodulation
EP1222281B1 (de) * 1999-09-30 2006-11-15 University of Washington Immunologisch relevante antigene aus herpes simplexvirus
GB0007088D0 (en) * 2000-03-23 2000-05-17 Torsana A S Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates
CA2438505A1 (en) * 2001-02-14 2002-09-12 Genzyme Corporation Altered peptide ligands
GB0215710D0 (en) 2002-07-05 2002-08-14 Isis Innovation Diagnostic method

Also Published As

Publication number Publication date
EP1774332A2 (de) 2007-04-18
WO2005117996A2 (en) 2005-12-15
EP2253956A3 (de) 2011-07-06
DE602005019054D1 (de) 2010-03-11
EP2184607B1 (de) 2012-07-11
JP2008507259A (ja) 2008-03-13
CA2567491A1 (en) 2005-12-15
EP1774332B1 (de) 2010-01-20
ES2390248T3 (es) 2012-11-08
EP2253956A2 (de) 2010-11-24
ES2341723T3 (es) 2010-06-25
CN1989410A (zh) 2007-06-27
HK1143417A1 (en) 2010-12-31
JP2011250787A (ja) 2011-12-15
WO2005117996A3 (en) 2006-06-22
US20060051358A1 (en) 2006-03-09
EP1774332A4 (de) 2008-06-25
EP2184607A1 (de) 2010-05-12

Similar Documents

Publication Publication Date Title
ATE456048T1 (de) Verfahren zur beurteilung von immunreaktionen
MA29528B1 (fr) Agents de fixation
ATE476908T1 (de) System und diagnoseverfahren zur optischen detektion von verdächtigen stellen einer gewebeprobe
DE602005017781D1 (de) Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
TR201816277T4 (tr) Çapraz-tür-spesifik bağlama alanı.
DE602006021292D1 (de) Tgf-beta-1-spezifische antikörper
ATE443260T1 (de) Kontrastmittel und verfahren zum imaging von naaldase oder psma
ATE528410T1 (de) Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration
MX2021009975A (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
PL2135881T3 (pl) Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu
DE602004030372D1 (de) Verfahren zur Bestimmung des relativen genetischen Risikos für Autismus
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
ATE424560T1 (de) Marker für neuromyelitis optica
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
WO2010041149A3 (en) Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
FI20011671A7 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
EA201100253A1 (ru) Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний
ATE505535T1 (de) Verfahren zur herstellung stabiler b-lymphozyten
ATE451618T1 (de) Verfahren zur identifizierung von epitopen in zusammenhang mit immunogenität bei biopharmazeutika
DE602005011642D1 (de) Bildgebung durch kohärente Streuung
WO2005040806A3 (en) Use of protein asc as a marker for breast cancer
ATE518003T1 (de) Verfahren zur identifizierung von cd4+-t-zellen- antigenen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties